Bio-Techne saw the highest growth of 2.24% in patent filings and 3.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Bio-Techne‘s patent filings and grants. Buy the databook here.
Bio-Techne has been focused on protecting inventions in United States(US) with ten publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 47% filings and 25% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and China(CN) patent Office are among the top ten patent offices where Bio-Techne is filings its patents. Among the top granted patent authorities, Bio-Techne has 38% of its grants in European Patent Office(EPO), 25% in United States(US) and 25% in China(CN).
In terms of grant share, Bio-Techne stands in fifth position among its competitors. and secured the top positions according to recent patent publication data.
Patents related to rare diseases and Covid-19 lead Bio-Techne's portfolio
Bio-Techne has the highest number of patents in rare diseases followed by, Covid-19 and genomics. For rare diseases, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Severe acute respiratory syndrome (sars) related patents lead Bio-Techne portfolio followed by image management, and leukemia
Bio-Techne has highest number of patents in severe acute respiratory syndrome (sars) followed by image management, leukemia, cyst.
For comprehensive analysis of Bio-Techne's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.